Moreover, the subgroup analysis indicated statistically significant higher incidences of infection with TNF inhibitors (OR = 2.41, 95% CI: 1.17–4.96;I2 = 0%;p = 0.02) and tocilizumab (OR: 1.54, 95% CI: 0.62–3.84;I2 = 53%;p = 0.35), as shown inFig. 5. The gene discussed is TNF; the disease is infection.